BioCardia Investor Relations Material
Latest events
Q2 2025
BioCardia
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from BioCardia Inc
Access all reports
BioCardia Inc. is a clinical-stage regenerative medicine company focused on developing cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. The company's leading therapeutic candidate, CardiAMP, is an autologous mononuclear cell therapy system designed for treating heart failure and chronic myocardial ischemia, alongside an allogeneic cell therapy for cardiac and pulmonary disease. BioCardia is also advancing an allogeneic cells therapeutic platform, in Phase I/II trial for ischemic heart failure treatment. Additionally, BioCardia offers the Helix biotherapeutic delivery system for precise heart muscle treatments and Morph deflectable guides and sheaths. The company is headquartered in Sunnyvale, California, and its shares are listed on the Nasdaq.
Latest articles
)
Verisure: Security Leader Ready for a Comeback IPO
Verisure, Europe's leading monitored alarm provider, is preparing a comeback IPO in 2025 that could be one of the year's most significant listings.
16 Sep 2025
)
Stephen J. Squeri: American Express Veteran Chairman and CEO
Stephen Squeri has spent over four decades at American Express, rising through the ranks to lead one of the world's most recognized brands.
15 Sep 2025
)
Where to? The Story of Uber
Uber's journey from rule-breaking disruptor to disciplined dual-app giant, now shaping the future of mobility, delivery, and autonomy.
5 Sep 2025
Ticker symbol
BCDA
Country
🇺🇸 United States